Certuity LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Certuity LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 37.9% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,718 shares of the biopharmaceutical company’s stock after buying an additional 472 shares during the quarter. Certuity LLC’s holdings in Regeneron Pharmaceuticals were worth $1,805,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. West Paces Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the period. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $26,000. Crewe Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $28,000. Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $33,000. Finally, Family Firm Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ REGN opened at $1,131.50 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The company has a market cap of $124.68 billion, a P/E ratio of 33.43, a P/E/G ratio of 3.13 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The stock has a fifty day moving average price of $1,113.10 and a 200 day moving average price of $1,020.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company’s revenue was up 12.3% on a year-over-year basis. During the same period last year, the firm earned $8.79 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insider Activity

In other news, CEO Leonard S. Schleifer sold 9,064 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $1,015.43, for a total transaction of $9,203,857.52. Following the completion of the sale, the chief executive officer now directly owns 55,134 shares in the company, valued at $55,984,717.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the transaction, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Leonard S. Schleifer sold 9,064 shares of the stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $1,015.43, for a total transaction of $9,203,857.52. Following the transaction, the chief executive officer now directly owns 55,134 shares in the company, valued at approximately $55,984,717.62. The disclosure for this sale can be found here. Insiders sold 20,625 shares of company stock worth $22,298,963 over the last ninety days. Corporate insiders own 7.48% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on REGN shares. JPMorgan Chase & Co. increased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, September 2nd. Truist Financial restated a “buy” rating and set a $1,200.00 price objective (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Wells Fargo & Company upped their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Guggenheim upped their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,108.95.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.